Edmond M. Kwan
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
Advancing Homologous Recombination Repair Mutation Testing in Prostate Cancer in Australia: Shifting the Focus to Hormone Sensitive Prostate Cancer.
Journal: Asia-Pacific journal of clinical oncology
Published: June 23, 2026
A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: April 09, 2026
NanoString profiling of DNA repair and apoptosis genes in testicular germ cell tumours with divergent chemotherapy outcomes.
Journal: Therapeutic advances in medical oncology
Published: March 25, 2026
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 01, 2025
Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: November 26, 2025
Beta-Decay Half-Lives beyond ^{54}Ca: A Systematic Survey of Decay Properties Approaching the Neutron Dripline.
Journal: Physical review letters
Published: August 06, 2025
Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 26, 2025
Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.
Journal: European urology oncology
Published: April 30, 2025
Safety and Efficacy of 20 Cycles of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 30, 2024
p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 25, 2024
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.
Journal: Nature medicine
Published: November 05, 2024
Last Updated: 09/26/2026